逍遥丸联合枸橼酸他莫昔芬片治疗乳腺增生症的临床疗效及对血清血管内皮生长因子、碱性成纤维细胞生长因子的影响  

Clinical efficacy of Xiaoyao Pill combined with tamoxifen citrate tablets on mammary gland hyperplasia and how to impact on serum vascular endothelial growth factor and basic fibroblast growth factor

作　　者：孙轶杰 王颖 SUN Yijie;WANG Ying(Department of Integrated Traditional Chinese and Western Medicine,The Second Outpatient Department of the Directly Affiliated Organs of Hebei Province,Shijiazhuang,Hebei 050051;Department of Function,The Second Outpatient Department of the Directly Affiliated Organs of Hebei Province,Shijiazhuang,Hebei 050051)

机构地区：[1]河北省直属机关第二门诊部中西医结合科,河北石家庄050051 [2]河北省直属机关第二门诊部功能科,河北石家庄050051

出　　处：《河北中医》2022年第5期797-800,共4页Hebei Journal of Traditional Chinese Medicine

基　　金：河北省中医药管理局2022年度中医药类科研计划课题(编号:2022381)。

摘　　要：目的观察逍遥丸联合枸橼酸他莫昔芬片治疗乳腺增生症的临床疗效及对血清血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)的影响。方法选择2020年5月至2021年8月河北省直属机关第二门诊部中西医结合科门诊乳腺增生症患者124例,按照随机数字表法分为2组,对照组62例给予枸橼酸他莫昔芬片,观察组62例加用逍遥丸,2组均治疗3个月。观察2组临床疗效;比较2组治疗前后乳腺疼痛、乳腺肿块大小及乳房肿块硬度评分及血清血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)水平变化;观察2组治疗期间不良反应发生情况。结果观察组总有效率96.77%(60/62),对照组总有效率79.03%(49/62),观察组疗效优于对照组(P<0.05)。治疗后2组患者乳腺疼痛、乳腺肿块大小及乳房肿块硬度评分均较本组治疗前降低(P<0.05),且观察组治疗后均低于对照组(P<0.05)。2组治疗后VEGF、bFGF水平均较本组治疗前降低(P<0.05),且观察组治疗后均低于对照组(P<0.05)。观察组未发生不良反应,对照组发生率为12.90%(8/62),2组比较差异有统计学意义(P<0.05)。结论逍遥丸联合枸橼酸他莫昔芬片治疗乳腺增生症能更好地改善患者乳腺症状,显著提高临床疗效,其机制可能是通过降低患者血清VEGF、bFGF水平,抑制乳腺血管生成,从而对乳腺增生症发挥治疗作用。Objective To study the clinical efficacy of Xiaoyao Pill combined with tamoxifen citrate tablets on mammary gland hyperplasia(MGH)and how to impact on serum vascular endothelial growth factor(VEGF)and basic fibroblast growth factor(bFGF).Methods Totally 124 MGH patients received treatment in the Mammary Gland Hyperplasia Clinic,Department of Integrated Traditional Chinese and Western Medicine,The Second Outpatient Department of the Directly Affiliated Organs of Hebei Province from May 2020 to August 2021 were selected and randomly divided into 2 groups,62 cases in each,on the basis of tamoxifen citrate tablet,and the observation group was additionally given Xiaoyao Pill.Both groups were treated for 3 months.The clinical efficacy of the two groups after treatment was analyzed.The serum levels of VEGF and bFGF,breast pain,breast tumor size and breast lump hardness scores were compared between 2 groups before and after treatment;the occurrence of adverse reactions was observed.Results The overall effective rate in the observation group 96.77%(60/62)was better than that in the control group 79.03%(49/62),(P<0.05).The score of breast pain,breast tumor size and breast lump hardness in two groups were less after treatment,which were less in the observation group than in the control group(P<0.05).The serum VEGF and bFGF levels in two group decreased(P<0.05),the observation group were more common(P<0.05).There was no adverse reaction in the observation group,and the incidence rate in the control group was 12.90%(8/62),and the difference was statistically significant(P<0.05).Conclusion For MGH patients,Xiaoyao Pill combined with tamoxifen citrate tablets can better improve the symptoms of patients with mammary hyperplasia and significantly improve the clinical efficacy.It may play a therapeutic role in mammary hyperplasia by reducing the levels of VEGF and bFGF in serum of patients and inhibiting mammary angiogenesis.

关 键 词：逍遥散 他莫昔芬 乳腺增生病 血管内皮生长因子A 成纤维细胞生长因子2 中西医结合疗法 

分 类 号：R655.820.58[医药卫生—外科学]